Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 5/2011

01-05-2011 | Original Article

Effects of baicalein on Sendai virus in vivo are linked to serum baicalin and its inhibition of hemagglutinin-neuraminidase

Authors: Jie Dou, Lili Chen, Ge Xu, Lei Zhang, Huimin Zhou, Hui Wang, Zhenzhen Su, Mengyun Ke, Qinglong Guo, Changlin Zhou

Published in: Archives of Virology | Issue 5/2011

Login to get access

Abstract

Parainfluenza viruses are significant respiratory-tract pathogens that are notorious for infecting children. However, there are no clinical drugs to control the infection caused by these viruses. Sendai virus (SeV) belongs to the family Paramyxoviridae and causes fatal pneumonia in mice, its natural host. Baicalein is a flavonoid derived from the root of Scutellaria baicalensis, which is a traditional Chinese medicine that has been used for hundreds of years and has demonstrated a variety of biological activities. Our findings reveal that oral administration of baicalein to mice infected with Sendai virus results in a significant reduction in virus titers in the lungs and protection from death. The in vivo inhibitory effects of baicalein on Sendai virus are determined by baicalin in the serum. The mean IC50 of baicalin was 0.71 μg/ml in an HA inhibition assay and 3.22 μg/ml in an NA inhibition assay. The mean IC50 of baicalin in a CPE assay was measured to be 0.70 μg/ml, and significant inhibition was observed in a plaque assay at a concentration of 1.6 μg/ml baicalin in overlay medium, which suggests that baicalein is a potential anti-parainfluenzaviral agent in vivo.
Literature
1.
Lamb RA, Parks GD (2006) Paramyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM (eds) Fields virology. Lippincott Williams & Wilkins, Philadelphia, pp 1449–1496
2.
Henrickson KJ, Kuhn SM, Savatski LL (1994) Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children. Clin Infect Dis 18:770–779PubMedCrossRef
3.
Chanock RM, Murphy BR, Collins PL (2001) Parainfluenza viruses. In: Knipe DM, Howley PM (eds) Fields virology, 4th edn. Lippincott/The Williams & Wilkins Co, Philadelphia, pp 1341–1379
4.
Markwell MAK (1991) New frontiers opened by the exploration of host cell receptors. In: Kingsbury DW (ed) The paramyxoviruses. Plenum Press Inc, New York, pp 407–425
5.
Lamb RA, Kolakofsky D (1996) The paramyxoviruses. In: Fields BN, Knipe DM, Howley PM (eds) Fields virology, 3rd edn. Lippincott-Raven Publishers, Philadelphia, pp 577–604
6.
Evers DL, Chao CF, Wang X, Zhang ZG, Huong SM, Huang ES (2005) Human cytomegalovirus - inhibitory flavonoids: Studies on antiviral activity and mechanism of action. Antivir Res 68:124–134PubMedCrossRef
7.
Akao T, Kawabata K, Yanagisawa E, Ishihara K, Mizuhara Y, Wakui Y et al (2000) Balicalin, the predominant flavone glucuronide of scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form. J Pharm Pharmacol 52:1563–1568PubMedCrossRef
8.
Lai MY, Hsiu SL, Tsai SY, Hou YC, Chao PDL (2003) Comparison of metabolic pharmacokineties of baicalin and baicalein in rats. J Pharm Pharmacol 55:205–209PubMedCrossRef
9.
Xing J, Chen XY, Sun YM, Luan Y, Zhong DF (2005) Interaction of baicalin and baicalein with antibiotics in the gastrointestinal tract. J Pharm Pharmacol 57:743–750PubMedCrossRef
10.
Liu TM, Jiang XH (2006) Investigation of the absorption mechanisms of baicalin and baicalein in rats. J Pharmacol Sci 95:1326–1333CrossRef
11.
Xu G, Dou J, Zhang L, Guo QL, Zhou CL (2010) Inhibitory effects of baicalein on the influenza virus in vivo is determined by baicalin in the serum. Biol Pharm Bull 33:238–243PubMedCrossRef
12.
Schepetiuk SK, Kok T (1993) The use of MDCK, MEK and LLC-MK2 cell lines with enzyme immunoassay for the isolation of influenza and parainfluenza viruses from clinical specimens. J Virol Methods 42:241–250PubMedCrossRef
13.
Boltz DA, Ilyushina NA, Arnold CS, Babu YS, Webster RG, Govorkova EA (2008) Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antivir Res 80:150–157PubMedCrossRef
14.
Iwama H, Amagaya S, Ogihara Y (1987) Effect of shosaikoto, a Japanese and Chinese traditional herbal medicinal mixture, on the mitogenic activity of lipopoly saccharide: a new pharmacological testing method. J Ethnopharmacol 21:45–53PubMedCrossRef
15.
Tsurita M, Kurokawa M, Imakita M, Fukuda Y, Watanabe Y, Shiraki K (2001) Early augmentation of interleukin (IL)-12 level in the airway of mice administered orally with clarithromycin or intranasally with IL-12 results in alleviation of influenza infection. J Pharmacol Exp Ther 298:362–368PubMed
16.
Venables WN, Ripley BD (1997) Modern Applied Statistics. Springer, New York, pp 223-242, 297-321, 345-350
17.
Cox DR (1972) Regression models and life-tables. J R Stat Soc (B) 34:187–220
18.
Nishioka Y, Kyotani X, Miyamura M (1992) Influence of time of administration of a shosaiko-to extract granule on blood concentration of its active constituents. Chem Pharm Bull 40:1335–1337PubMed
19.
Miocinovic R, McCabe NP, Keck RW, Jankun J, Hampton JA, Selman SH (2005) In vivo and in vitro effect of baicalein on human prostate cancer cells. Int J Oncol 26:241–246PubMed
20.
Wu JA, Attele AS, Zhang L, Yuan CS (2001) Anti-HIV activity of medicinal herbs: usage and potential development. Am J Chin Med 29:69–81PubMedCrossRef
21.
Shen YC, Chiou WF, Chou YC, Chen CF (2003) Mechanisms in mediating the anti-inflammatory effects of baicalin and baicalein in human leukocytes. Eur J Pharmacol 465:171–181PubMedCrossRef
22.
Ciesielska E, Wolszczak M, Gulanowski B, Szulawska A, Kochman A, Metodiewa D (2004) In vitro antileukemic, antioxidant and prooxidant activities of Antoksyd S (C/E/XXI): a comparison with baicalin and baicalein. In Vivo 18:497–503PubMed
23.
Woo AYH, Cheng CHK, Waye MMY (2005) Baicalein protects rat cardiomyocytes from hypoxia/reoxygenation damage via a prooxidant mechanism. Cardiovasc Res 65:244–253PubMedCrossRef
24.
Ma Z, Otsuyama K, Liu SQ, Abroun S, Ishikawa H, Tsuyama N et al (2005) Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells. Blood 105:3312–3318PubMedCrossRef
25.
Ciesielska E, Gwardys A, Metodiewa D (2002) Anticancer, antiradical and antioxidative actions of novel Antoksyd S and its major components, baicalin and baicalein. Anticancer Res 22:2885–2891PubMed
26.
Evers DL, Chao C, Wang X, Zhang Z, Huong S, Huang E (2005) Human cytomegalovirus-inhibitory flavonoids: studies on antiviral activity and mechanism of action. Antivir Res 68:124–134PubMedCrossRef
27.
Collins PL, Mottet G (1991) Homooligomerization of the hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3 occurs before the acquisition of correct intramolecular disulfide bonds and mature immunoreactivity. J Virol 65:2362–2371PubMed
28.
Henrickson KJ (1991) Monoclonal antibodies to human parainfluenza virus type 1 detect major antigenic changes in clinical isolates. J Infect Dis 164:1128–1134PubMedCrossRef
29.
Iorio RM, Bratt MA (1984) Neutralization of Newcastle disease virus by monoclonal antibodies to the hemagglutininneuraminidase glycoprotein: requirement for antibodies to four sites for complete neutralization. J Virol 51:445–451PubMed
30.
de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC et al (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353:2667–2672PubMedCrossRef
31.
Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH et al (2005) Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108PubMedCrossRef
32.
Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, Zhang Y et al (2007) Surveillance of resistance to adamantanes among influenza A (H3N2) and A (H1N1) viruses isolated worldwide. J Infect Dis 196:249–257PubMedCrossRef
33.
Hata M, Tsuzuki M, Goto Y, Kumagai N, Harada M, Hashimoto M et al (2007) High frequency of amantadine-resistant influenza A (H3N2) viruses in the 2005–2006 season and rapid detection of amantadine-resistant influenza A (H3N2) viruses by MAMA-PCR. Jpn J Infect Dis 60:202–204PubMed
34.
Ilyushina NA, Bovin NV, Webster RG, Govorkova EA (2006) Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antivir Res 70:121–131PubMedCrossRef
35.
Govorkova EA, Fang HB, Tan M, Webster RG (2004) Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic antiinfluenza virus effects in MDCK cells. Antimicrob Agents Chemother 48:4855–4863PubMedCrossRef
36.
Smee DF, Bailey KW, Morrison AC, Sidwell RW (2002) Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 48:88–93PubMedCrossRef
37.
Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD (2009) Effects of Double Combinations of Amantadine, Oseltamivir, and Ribavirin on Influenza A (H5N1) Virus Infections in Cell Culture and in Mice. Antimicrob Agents Chemother 53:2120–2128PubMedCrossRef
38.
Ilyushina NA, Hay A, Yilmaz N, Boon ACM, Webster RG, Govorkova EA (2008) Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother 52:3889–3897PubMedCrossRef
39.
Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA (2007) Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antiviral Ther 12:363–370
40.
Eriksson B, Helgstrand E, Johansson NG, Larsson A, Misiorny A, Nore′n JO et al (1977) Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother 11:946–951PubMed
Metadata
Title
Effects of baicalein on Sendai virus in vivo are linked to serum baicalin and its inhibition of hemagglutinin-neuraminidase
Authors
Jie Dou
Lili Chen
Ge Xu
Lei Zhang
Huimin Zhou
Hui Wang
Zhenzhen Su
Mengyun Ke
Qinglong Guo
Changlin Zhou
Publication date
01-05-2011
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 5/2011
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-011-0917-z

Other articles of this Issue 5/2011

Archives of Virology 5/2011 Go to the issue

Erratum

Erratum to: Evidence for recombination between vaccine and wild-type mumps virus strains

Original Article

The nuclear localization signal sequence of porcine circovirus type 2 ORF2 enhances intracellular delivery of plasmid DNA

Annotated Sequence Record

Molecular characterization of a new begomovirus and divergent alphasatellite from tomato in Cameroon

Original Article

Smurf2 alters BPV1 trafficking and decreases infection

Annotated Sequence Record

Complete genome sequence of Celery mosaic virus and its relationship to other members of the genus Potyvirus

Original Article

Molecular epidemiology of foot-and-mouth disease virus serotypes A and O with emphasis on Korean isolates: temporal and spatial dynamics
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits